The HCPLive rheumatoid arthritis page is a comprehensive resource for clinical news and insights on arthritis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for RA, and more.
May 1st 2024
Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.
Long-Term Cumulative Joint Inflammation Linked to Joint Damage Progression in Rheumatoid Arthritis
In the post-hoc analysis, an association between cumulative local joint swelling and progression of radiographic damage in the same joint was observed in patients with rheumatoid arthritis.
Adverse Reactions, Disease Activity Cited as Disease-Dependent Factors for Biosimilar Refusal
Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.
Patients with Rheumatoid Arthritis Satisfied with Switch to Adalimumab Biosimilar
Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.
ACR/EULAR Recommendations for Switching Therapies in RA
December 28th 2022Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, discuss American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) recommendations regarding appropriate timing when changing therapies in managing RA.
Treatment Journey of Patients With Rheumatoid Arthritis (RA)
December 7th 2022Drs Nehad Soloman, Joy Schechtman, and Robert Levine describe the treatment path from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic or targeted disease-modifying antirheumatic drugs (b/tsDMARDs) for a typical rheumatoid arthritis (RA) patient.